Ultragenyx Pharmaceutical Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Ultragenyx Pharmaceutical Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2014 to Q3 2025.
  • Ultragenyx Pharmaceutical Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2025 was -$180M, a 34.8% decline year-over-year.
  • Ultragenyx Pharmaceutical Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2025 was -$577M, a 2.79% decline year-over-year.
  • Ultragenyx Pharmaceutical Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was -$568M, a 6.72% increase from 2023.
  • Ultragenyx Pharmaceutical Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$608M, a 13.3% increase from 2022.
  • Ultragenyx Pharmaceutical Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$702M, a 54.9% decline from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)

Ultragenyx Pharmaceutical Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$577M -$180M -$46.3M -34.8% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 -$530M -$114M +$16.7M +12.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-06
Q1 2025 -$547M -$150M +$20.5M +12% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 -$568M -$133M -$6.51M -5.13% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-19
Q3 2024 -$561M -$133M +$25.8M +16.2% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 -$587M -$131M +$28.4M +17.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-06
Q1 2024 -$615M -$170M -$6.75M -4.13% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 -$608M -$127M +$26.4M +17.2% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-19
Q3 2023 -$635M -$159M +$79.8M +33.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$715M -$159M -$1.24M -0.78% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 -$713M -$163M -$11.7M -7.72% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-03
Q4 2022 -$702M -$153M -$30.8M -25.2% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-19
Q3 2022 -$671M -$239M -$166M -228% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$505M -$158M -$35.9M -29.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 -$469M -$152M -$16M -11.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 -$453M -$122M -$98.5M -411% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 -$354M -$72.8M -$4.28M -6.25% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$350M -$122M -$148M -574% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-29
Q1 2021 -$203M -$136M -$17.1M -14.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$185M -$23.9M +$67.3M +73.8% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-17
Q3 2020 -$253M -$68.5M +$44.2M +39.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$297M $25.7M +$125M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$422M -$119M -$22.1M -22.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$399M -$91.2M -$3.54M -4.04% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 -$396M -$113M -$25.6M -29.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-27
Q2 2019 -$370M -$99M -$46.3M -88% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-30
Q1 2019 -$324M -$96.5M -$127M -419% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$197M -$87.7M +$10.2M +10.5% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-12
Q3 2018 -$207M -$87.1M -$7.84M -9.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 -$200M -$52.6M +$20.3M +27.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-02
Q1 2018 -$220M $30.3M +$98.6M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$318M -$97.9M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-14
Q3 2017 -$79.2M -$14.3M -22.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$72.9M -$16M -28% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 -$68.3M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q3 2016 -$64.9M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-03
Q2 2016 -$56.9M Apr 1, 2016 Jun 30, 2016 10-Q 2017-07-28

Ultragenyx Pharmaceutical Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$568M +$40.9M +6.72% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-19
2023 -$608M +$93.3M +13.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-19
2022 -$702M -$249M -54.9% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-19
2021 -$453M -$268M -144% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$185M +$214M +53.6% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-17
2019 -$399M -$202M -103% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$197M +$121M +38.1% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-12
2017 -$318M -$72.5M -29.5% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-14
2016 -$246M -$100M -68.8% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-20
2015 -$146M -$85.8M -144% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-21
2014 -$59.8M Jan 1, 2014 Dec 31, 2014 10-K 2017-02-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.